January 26th 2023
The data may help explain why COVID-19 patients experience dangerous secondary infections.
January 22nd 2023
A Chinese epidemiologist made this claim this weekend as the country gathers for its Lunar New Year celebrations.
January 20th 2023
Click on the slideshow images to read the full stories featured in this weekly infectious disease recap.
January 17th 2023
Tibetan Buddhist monks, who meditate regularly, had vastly different gut microbiomes than the non-meditating control group.
Preclinical testing suggests that a newly developed SARS-CoV-2 vaccine could protect against current and future variants.
A New Approach to Treatment-Resistant C difficile Infection
Fecal microbiota transplant (FMT) is a promising option for patients struggling with CDI recurrences. But how can we ensure the treatment is successful?
Fidaxomicin, Vancomycin, or Metronidazole? Comparing C Difficile Treatment Cost-Efficacy
Though the drug is initially more expensive, treating C diff infection with fidaxomicin reduced costs overall by reducing CDI recurrences.
Vitamin D Supplementation Appears to Offer Protective Benefits Against COVID-19
A new report finds veterans who took vitamin D supplements were less likely to get COVID-19 and less likely to die within 30 days of infection.
Infectious Disease Update: This Week's Top 5 Stories
With major updates in HIV, C difficile, hepatitis, yeast infections, and skin and soft tissue infections, this week's Infectious Disease Update has something for everyone.
New Therapeutic Offers Promise for Recurrent C Diff Infection
An easy-to-administer oral biologic kept repeat C difficile infections at bay in a new study.
FDA PDUFA Date Set for C diff Drug, SER-109
The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.
FMT Trial Halted Early Due to Clear Efficacy for Recurrent C Difficile
A fecal microbiota transplant (FMT) trial was halted early due to clear evidence the treatment was superior to placebo.
FMT Cost-Effective for 90% of Recurrent C Difficile Infections
Compared to fidaxomicin and vancomycinfecal, microbiota transplant (FMT) was the most cost-effective treatment for first and subsequent recurrent C difficile infection.
The Shrinking Incubation Period of COVID-19
The incubation period of the original, wild-type COVID-19 strain was 6.65 days, while the Omicron variant's incubation period has shortened to 3.42 days.
Recurrence Escalates Financial Burden of CDI
Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.
Investigational Microbiome Therapeutic SER-109 Reduces C Difficile Recurrence
SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.
Investigational Therapy SER-109 Prevents Recurrent C Difficile Infection
Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.
FDA Approves 2 Vonoprazan Treatments for Helicobacter Pylori Infection
Today, the FDA approved vonoprazan dual and triple therapies, developed by Phathom Pharmaceuticals to treat adults with H. pylori infection.
Continuous Enteral Vancomycin Helpful in Cases of Severe Recurrent CDI
In a small retrospective study, 7 of 11 patients experienced clinical improvement.
New Vibrio Bacteria in UK Waters as Sea Temperatures Rise
Rising sea temperatures cause Vibrio species, bacteria linked to gastroenteritis, to be identified for the first time in UK waters.
Lower BMI Increased Risk of C Diff Infection in Elderly Pneumonia Patients
Underweight elderly pneumonia patients were more likely to contract C difficile infection.
Higher Stool Toxin Concentrations Increase Severity of Clostridioides Difficile Infection
For the first time, investigators proved that a higher presence of Clostridioides difficile bacteria and toxins cause a more severe infection.
C Difficile Bacteria Pervasive in Non-Healthcare Settings Worldwide, Found on 45% of Shoe Soles
A global study of C. difficile isolates worldwide found a very high prevalence of the bacteria on shoe soles.
A Case of Candida Albicans Ventriculitis Secondary to E Coli Ventriculoperitoneal Shunt Infection
Rare cases of health care–associated meningitis and ventriculitis in adults caused by Candida species are associated with recent bacterial meningitis and broad-spectrum antibiotic use.
Paradigm Shift in the Management of Clostridioides difficile Infections
Clostridioides difficile Infection: Diagnosis, Testing, Screening, and Treatment
Investigators apply guidelines into practical management strategies.
Stem Cell Patients with C Difficile Benefit from Vancomycin, Fidaxomicin
An assessment of the frontline agents show similarities infection cure and recurrence rates at 30 days.
Fidaxomicin, Vancomycin Provide Similar C Difficile Initial Cure, Mortality Rates
A meta-analysis suggest the 2 first-line C diff therapies provide similar outcomes, yet differ in recurrent infection risk.
How Well Can Rotavirus Vaccines Protect Against RVGE?
A study shows countries with the highest income levels had greater vaccine protection against rotavirus gastroenteritis (RVGE).
Advances in the Management of C difficile
Experts discuss the bacteria’s transmission in the community setting, how to reduce disease and economic burdens, and ways to improve quality of life for patients.
Is There a Better β-Lactam for Viridans Group Streptococci?
C. Difficile: Clinical Practice Guidelines and Treatment Options
Recommendations for treating C. difficile upon a first recurrence as well as following multiple recurrences based on currently available treatment options and recommendations by the IDSA/SHEA clinical practice guidelines.
Screening for C. Difficile
A panel of clinicians recognize the challenges associated with screening patients for the C. difficile infection and highlight factors that should prompt someone for an evaluation.
Testing for C. Difficile Infections
Types of testing algorithms used in clinical practice to help clarify a diagnosis of C. difficile infection.
C. Difficile: A Differential Diagnosis
Important things to understand about diagnosing C. difficile and recommendations for properly differentiating the condition from other diseases when working-up a patient.
2 Clarke Drive Cranbury, NJ 08512